전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,399 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTAAVCurated CoreFDAstaleSpark TherapeuticsApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 7Status Approved
CGTCurated CoreFDAstaleOrchard Therapeutics (Kyowa Kir…Approved

atidarsagene autotemcel (Lenmeldy, OTL-200, Libmeldy, arsa-cel)

Pre-symptomatic and early-symptomatic metachromatic leukodystrophy · ARSA (arylsulfatase A) gene

#ARSAarylsulfataseAgene#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 3Status Approved
CGTCurated CoreFDAstalebluebird bioApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 2Status Approved
ADCLimited DataFDAstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA-approved#antibody-drug-conjugate+1
Trials 1Status Active
ADCLimited DataFDAGenmabApproved

TISOTUMAB VEDOTIN-TFTV (TISOTUMAB VEDOTIN-TFTV)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA-approved#antibody-drug-conjugate+2
Trials 0Status Approved
AntibodyCurated CorestaleBristol Myers SquibbPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 470Status Active
AntibodyCurated CorestaleJanssenApproved

Remicade® (Remicade®)

Crohn's Disease · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Approved#BioJungboMoa-pick#Popular+3
Trials 406Status Active
AntibodyCurated CorestaleRochePhase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+3
Trials 233Status Discontinued
ADCLimited DatastaleAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 226Status Recruiting
ADCLimited DatastaleSeagenvedotin combined with the i…Preclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 219Status Active
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 212Status Recruiting
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
ADCLimited DatastaleSeagenVedotin: A Retrospective Co…Approved

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Approved#Popular#antibody-drug-conjugate+4
Trials 195Status Active
AntibodyCurated CorestaleAstraZenecaPhase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 195Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 185Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#Popular#monoclonal-antibody+1
Trials 185Status Active
AntibodyLimited DatastaleBeiGenePhase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#Popular#monoclonal-antibody+2
Trials 184Status Recruiting
AntibodyLimited DatastaleRochePhase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#Popular#monoclonal-antibody+2
Trials 183Status Recruiting
ADCLimited DatastaleRochevedotin plus rituximab, cyc…Phase 2

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 183Status Active
ADCLimited DatastaleRochevedotin plus rituximab, cyc…Phase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 177Status Discontinued

4 / 120 pages

← PreviousNext →